Gilteritinib (ASP2215)

Name: Gilteritinib (ASP2215)
Brand: Selleck Chemicals
SKU: S7754
Rating: 5 (1 reviews)

For research use only.

Catalog No.S7754

1 publication

Gilteritinib (ASP2215) Chemical Structure

Molecular Weight(MW): 552.71

Gilteritinib(ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).

Selleck's Gilteritinib (ASP2215) has been cited by 1 publication

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0832

PubMed: 31320594

Purity & Quality Control

Choose Selective FLT3 Inhibitors

Biological Activity

Description

Targets

FLT3 ^[1] (Cell-free assay)	Axl ^[1] (Cell-free assay)
0.29 nM	0.73 nM

In vitro

Gilteritinib demonstrates potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib decreases the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models. Gilteritinib inhibits the activity of eight of the 78 tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and AXL) or 5 nM (TRKA, ROS, RET, and MER)^[1]. Gilteritinib treatment for 48h results in an induction of apoptosis in MV4-11 cells as determined by an increase in annexin V-positive cells. Gilteritinib also decreases the expression of anti-apoptotic proteins such as MCL-1, BCL2L10, and survivin, which are reported to be important in chemotherapy sensitivity, following 24h treatment^[2].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MV4-11 cells	NUTTWFdjS2WubDDjfYNt\SCjc4PhfS=>	MofsNUwhOyxiMUCsJIFv\CB\|MDDuUS=>	Mn\tNlQhcA>?	Ml;uWIhmKG2nYX6gdJJweG:{dHnvckBw\iCPVkStNVEh[2WubIOgbY4hTzFicHjhd4Uhf2W{ZTDzbYdvcW[rY3HueIx6KGmwY4LlZZNm\CCjdDDnbYx1\XKrdHnubYIh[2:wY3XueJJifGmxboOgc4YhOyBqNkmuNEU8KFB:MD6wNUkh[W6mIEGwJI5OKCh5MD63KVshWDxyLkCwNUkv	MmDLN\|ExPjlyMUW=
MOLM-13 cells	NHf1eplCeG:ydH;zbZMh[XO\|YYm=	NHPLdJcyNCB\|LDCxNEwhOzBuIHHu[EAyODBibl2=	MlvIOFghcA>?	M{XOeZNq\26rZnnjZY51KGmwY4LlZZNmeyCrbjD0bIUheGW{Y3XueIFo\SCxZjDhco5mgGmwIG[tdI9{cXSrdnWgZ4VtdHNiYYSgZ49v[2WwdILheIlwdnNib3[gN\|Ahdk1iKEOyMlAmMSCjbnSgNVAxKG6PIDi1Nk41LSlidnXyd5V{KGOxboTyc4whMDRwMTWp	NY[1T\|VnOzFyNkmwNVU>
32D/TKD cells	NFf0TZpHfW6ldHnvckBie3OjeR?=	Mkf4OVAhdk4EoB?=	MVq2JIg>	MlW2TY5pcWKrdH;uJI9nKHSqZTDwbI9{eGixconsZZRqd25ib3[gRYt1KG:wIGSzNFg>	NELkVFkzQTVyN{[2NC=>
TF-1 cells	MnLOSpVv[3Srb36gZZN{[Xl?	NGWxbHIxNCB{MDygPFAtKDJyMDDhcoQhPTByIH7N	MnTpNUBp	M1PQcIdqdHSncnn0bY5q[iCqYYOgZY4hUUN3MDDh[4FqdnO2IIfpcIQufHmyZTDjMWtqfCCxZjCxNFIhdk1?	M4jIS\|I4QTB6OEix

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT5 / STAT5 / p-AKT / AKT / p-ERK / ERK; PubMed: 28516360 Invest New Drugs Immunoblot for phosphorylated AKT, ERK, and STAT5 in gilteritinib-treated MV4–11 cells. Blots from one study, which was done in triplicate, are shown. p-c-kit / c-kit; PubMed: 27908881 Blood TF-1 cells were treated with increasing concentrations gilteritinib in RPMI/10% FBS for 1 hour. Immunoprecipitation and immunoblotting were performed to detect the phosphorylation status of c-Kit and total c-Kit. p-FLT3(Y591) / FLT3; PubMed: 30344940 Oncotarget Cells were treated with or without 10 nM gilteritinib, or midostaurin for 6 h, and immunoblotting was performed using the indicated antibodies.	28516360 27908881 30344940

In vivo

In vivo, gilteritinib is distributed at high levels in xenografted tumors after oral administration. The decreased FLT3 activity and high intratumor distribution of gilteritinib translates to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML. This antitumor activity is associated with a durable inhibition of phospho-FLT3 and phospho-STAT5. Furthermore, treatment with gilteritinib decreases the leukemic burden and prolongs survival in a mouse IBMT model. No overt toxicity is seen in mouse models treated with gilteritinib^[1].

Protocol

Cell Research: ^[1]	- Collapse Cell lines: MV4-11 cells Concentrations: 0.1 nM, 1 nM, and 10 nM Incubation Time: 2 h Method: MV4-11 cells are treated with DMSO or increasing concentrations of gilteritinib for 2 hours. Immunoprecipitation and immunoblot for phosphorylated FLT3 and total FLT3 are performed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: MV4-11 xenografted mice (Nude mice) Dosages: 1 mg/kg, 6 mg/kg, and 10 mg/kg Administration: oral (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (180.92 mM)
	Ethanol	85 mg/mL (153.78 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gilteritinib (ASP2215) SDF

Molecular Weight	552.71
Formula	C₂₉H₄₄N₈O₃
CAS No.	1254053-43-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CCC1=NC(=C(NC2=CC=C(N3CCC(CC3)N4CCN(C)CC4)C(=C2)OC)N=C1NC5CCOCC5)C(N)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03730012	Active not recruiting	Drug: gilteritinib\|Drug: atezolizumab	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	June 19 2019	Phase 1\|Phase 2
NCT03964038	Completed	Drug: gilteritinib\|Drug: gilteritinib mini tablet	Healthy Volunteer	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	May 21 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Do you have recommendations for the formulation of giltertinib (ASP-2215) in mice (for in vivo studies)?
Answer:
You can use "5% DMSO+40% PEG 300+5% Tween 80+ddH2O" clear at 5mg/ml as a IP formula.

FLT3 Signaling Pathway Map

Related FLT3 Products

Dovitinib (TKI258) Lactate ^New

Dovitinib (TKI258) Lactate is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
AMG 925 ^New

AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Quizartinib (AC220)

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.

Features:The most potent cellular FLT3-ITD inhibitor.
Dovitinib (TKI-258)

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.
ENMD-2076

ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

Features:Multi-target, anti-proliferative, pro-apoptotic activity, anti-angiogenic.
KW-2449

KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.

Features:Investigated as a FLT3 inhibitor in clinical trials, with others in early development.
Tandutinib (MLN518)

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.
Dovitinib (TKI-258) Dilactic Acid

Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
TCS 359

TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.

Features:Highly potent and selective.

Choose Your Country or Region

By Signaling Pathways

By product type

Gilteritinib (ASP2215)